{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:50:31Z","timestamp":1791575431432,"version":"4.3.4"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-01013-y","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:31:08Z","timestamp":1791527468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond a cancer stem cell marker: molecular state dependent functions of CD133 and state targeted therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Lin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanye","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanbing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunPeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"12","key":"1013_CR1","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1182\/blood.V90.12.5002","volume":"15","author":"AH Yin","year":"1997","unstructured":"Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood Dec. 1997;15(12):5002\u201312.","journal-title":"Blood Dec"},{"issue":"12","key":"1013_CR2","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1182\/blood.V90.12.5013","volume":"15","author":"S Miraglia","year":"1997","unstructured":"Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood Dec. 1997;15(12):5013\u201321.","journal-title":"Blood Dec"},{"issue":"23","key":"1013_CR3","doi-asserted-by":"publisher","first-page":"12425","DOI":"10.1073\/pnas.94.23.12425","volume":"11","author":"A Weigmann","year":"1997","unstructured":"Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A Nov. 1997;11(23):12425\u201330. https:\/\/doi.org\/10.1073\/pnas.94.23.12425.","journal-title":"Proc Natl Acad Sci U S A Nov"},{"issue":"4","key":"1013_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.biocel.2004.08.010","volume":"37","author":"SV Shmelkov","year":"2005","unstructured":"Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133\/CD133\/Prominin-1. Int J Biochem Cell Biol Apr. 2005;37(4):715\u20139. https:\/\/doi.org\/10.1016\/j.biocel.2004.08.010.","journal-title":"Int J Biochem Cell Biol Apr"},{"issue":"1","key":"1013_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.2283","volume":"214","author":"D Mizrak","year":"2008","unstructured":"Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol Jan. 2008;214(1):3\u20139. https:\/\/doi.org\/10.1002\/path.2283.","journal-title":"J Pathol Jan"},{"issue":"7015","key":"1013_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"18","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature Nov. 2004;18(7015):396\u2013401. https:\/\/doi.org\/10.1038\/nature03128.","journal-title":"Nature Nov"},{"issue":"7123","key":"1013_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"4","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature Jan. 2007;4(7123):106\u201310. https:\/\/doi.org\/10.1038\/nature05372.","journal-title":"Nature Jan"},{"issue":"7123","key":"1013_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature05384","volume":"4","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature Jan. 2007;4(7123):111\u20135. https:\/\/doi.org\/10.1038\/nature05384.","journal-title":"Nature Jan"},{"issue":"7","key":"1013_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1053\/j.gastro.2007.04.025","volume":"132","author":"S Ma","year":"2007","unstructured":"Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem\/progenitor cells. Gastroenterology Jun. 2007;132(7):2542\u201356. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.025.","journal-title":"Gastroenterology Jun"},{"issue":"3","key":"1013_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.cdd.4402283","volume":"15","author":"A Eramo","year":"2008","unstructured":"Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ Mar. 2008;15(3):504\u201314. https:\/\/doi.org\/10.1038\/sj.cdd.4402283.","journal-title":"Cell Death Differ Mar"},{"issue":"4","key":"1013_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11888-011-0106-1","volume":"7","author":"X Yu","year":"2011","unstructured":"Yu X, Lin Y, Yan X, Tian Q, Li L, Lin EH. CD133, Stem Cells, and Cancer Stem Cells: Myth or Reality? Curr Colorectal Cancer Rep Dec. 2011;7(4):253\u20139. https:\/\/doi.org\/10.1007\/s11888-011-0106-1.","journal-title":"Curr Colorectal Cancer Rep Dec"},{"key":"1013_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2018.10.013","volume":"106","author":"GY Liou","year":"2019","unstructured":"Liou GY. CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol Jan. 2019;106:1\u20137. https:\/\/doi.org\/10.1016\/j.biocel.2018.10.013.","journal-title":"Int J Biochem Cell Biol Jan"},{"issue":"6","key":"1013_CR13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.stem.2020.04.008","volume":"4","author":"P Vora","year":"2020","unstructured":"Vora P, Venugopal C, Salim SK, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell Jun. 2020;4(6):832\u2013e8446. https:\/\/doi.org\/10.1016\/j.stem.2020.04.008.","journal-title":"Cell Stem Cell Jun"},{"issue":"1","key":"1013_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","volume":"9","author":"PM Glumac","year":"2018","unstructured":"Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med Jul. 2018;9(1):18. https:\/\/doi.org\/10.1186\/s40169-018-0198-1.","journal-title":"Clin Transl Med Jul"},{"issue":"7","key":"1013_CR15","doi-asserted-by":"publisher","first-page":"e1440169","DOI":"10.1080\/2162402x.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen M, Wu Z, et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018;7(7):e1440169. https:\/\/doi.org\/10.1080\/2162402x.2018.1440169.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1013_CR16","doi-asserted-by":"publisher","first-page":"1846926","DOI":"10.1080\/2162402x.2020.1846926","volume":"25","author":"H Dai","year":"2020","unstructured":"Dai H, Tong C, Shi D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology Nov. 2020;25(1):1846926. https:\/\/doi.org\/10.1080\/2162402x.2020.1846926.","journal-title":"Oncoimmunology Nov"},{"issue":"6","key":"1013_CR17","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1172\/jci34401","volume":"118","author":"SV Shmelkov","year":"2008","unstructured":"Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133\u2009+\u2009and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest Jun. 2008;118(6):2111\u201320. https:\/\/doi.org\/10.1172\/jci34401.","journal-title":"J Clin Invest Jun"},{"issue":"4","key":"1013_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/ijc.23130","volume":"15","author":"J Wang","year":"2008","unstructured":"Wang J, Sakariassen P, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer Feb. 2008;15(4):761\u20138. https:\/\/doi.org\/10.1002\/ijc.23130.","journal-title":"Int J Cancer Feb"},{"issue":"11","key":"1013_CR19","doi-asserted-by":"publisher","first-page":"e3655","DOI":"10.1371\/journal.pone.0003655","volume":"3","author":"CE Griguer","year":"2008","unstructured":"Griguer CE, Oliva CR, Gobin E, et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE. 2008;3(11):e3655. https:\/\/doi.org\/10.1371\/journal.pone.0003655.","journal-title":"PLoS ONE"},{"issue":"4","key":"1013_CR20","doi-asserted-by":"publisher","first-page":"e61133","DOI":"10.1371\/journal.pone.0061133","volume":"8","author":"CS Hsu","year":"2013","unstructured":"Hsu CS, Tung CY, Yang CY, Lin CH. Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620. PLoS ONE. 2013;8(4):e61133. https:\/\/doi.org\/10.1371\/journal.pone.0061133.","journal-title":"PLoS ONE"},{"issue":"5","key":"1013_CR21","doi-asserted-by":"publisher","first-page":"e10714","DOI":"10.1371\/journal.pone.0010714","volume":"19","author":"TM Elsaba","year":"2010","unstructured":"Elsaba TM, Martinez-Pomares L, Robins AR, et al. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One May. 2010;19(5):e10714. https:\/\/doi.org\/10.1371\/journal.pone.0010714.","journal-title":"PLoS One May"},{"key":"1013_CR22","doi-asserted-by":"publisher","unstructured":"Kholodenko IV, Saidova AA, Potashnikova DM, et al. Contrasting Impacts of targeted disruption of the cancer stem cell marker CD133 and Its epigenetic regulator TRIM28 in colorectal cancer cells. Int J Mol Sci. 2025;26(22). https:\/\/doi.org\/10.3390\/ijms262210862.","DOI":"10.3390\/ijms262210862"},{"issue":"3","key":"1013_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/mpa.0000000000000460","volume":"45","author":"CC Weng","year":"2016","unstructured":"Weng CC, Kuo KK, Su HT, et al. Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation. Pancreas Mar. 2016;45(3):443\u201357. https:\/\/doi.org\/10.1097\/mpa.0000000000000460.","journal-title":"Pancreas Mar"},{"key":"1013_CR24","doi-asserted-by":"publisher","unstructured":"Simbulan-Rosenthal CM, Dougherty R, Vakili S, et al. CRISPR-Cas9 knockdown and induced expression of CD133 reveal essential roles in melanoma invasion and metastasis. Cancers (Basel). 2019;11(10). https:\/\/doi.org\/10.3390\/cancers11101490.","DOI":"10.3390\/cancers11101490"},{"issue":"1","key":"1013_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s11658-024-00554-0","volume":"26","author":"P Pleska\u010d","year":"2024","unstructured":"Pleska\u010d P, Fargeas CA, Veselska R, Corbeil D, Skoda J. Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease. Cell Mol Biol Lett Mar. 2024;26(1):41. https:\/\/doi.org\/10.1186\/s11658-024-00554-0.","journal-title":"Cell Mol Biol Lett Mar"},{"issue":"6","key":"1013_CR26","first-page":"563","volume":"25","author":"E Irollo","year":"2013","unstructured":"Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res Sep. 2013;25(6):563\u201381.","journal-title":"Am J Transl Res Sep"},{"issue":"6","key":"1013_CR27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1399-0039.2007.00825.x","volume":"69","author":"CA Fargeas","year":"2007","unstructured":"Fargeas CA, Huttner WB, Corbeil D. Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens Jun. 2007;69(6):602\u20136. https:\/\/doi.org\/10.1111\/j.1399-0039.2007.00825.x.","journal-title":"Tissue Antigens Jun"},{"issue":"10","key":"1013_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/cr.2008.270","volume":"18","author":"K Tabu","year":"2008","unstructured":"Tabu K, Sasai K, Kimura T, et al. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res Oct. 2008;18(10):1037\u201346. https:\/\/doi.org\/10.1038\/cr.2008.270.","journal-title":"Cell Res Oct"},{"issue":"47","key":"1013_CR29","doi-asserted-by":"publisher","first-page":"41046","DOI":"10.1074\/jbc.M111.261545","volume":"25","author":"AB Mak","year":"2011","unstructured":"Mak AB, Blakely KM, Williams RA, et al. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem Nov. 2011;25(47):41046\u201356. https:\/\/doi.org\/10.1074\/jbc.M111.261545.","journal-title":"J Biol Chem Nov"},{"issue":"4","key":"1013_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.celrep.2012.09.016","volume":"25","author":"AB Mak","year":"2012","unstructured":"Mak AB, Nixon AM, Kittanakom S, et al. Regulation of CD133 by HDAC6 promotes \u03b2-catenin signaling to suppress cancer cell differentiation. Cell Rep Oct. 2012;25(4):951\u201363. https:\/\/doi.org\/10.1016\/j.celrep.2012.09.016.","journal-title":"Cell Rep Oct"},{"key":"1013_CR31","doi-asserted-by":"publisher","unstructured":"Boivin D, Labb\u00e9 D, Fontaine N et al. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry. 2009;48(18):3998\u20134007. https:\/\/doi.org\/10.1021\/bi900159d.","DOI":"10.1021\/bi900159d"},{"key":"1013_CR32","doi-asserted-by":"publisher","unstructured":"Yang F, Xing Y, Li Y, et al. Monoubiquitination of cancer stem cell marker CD133 at lysine 848 regulates its secretion and promotes cell migration. Mol Cell Biol. 2018;38(15). https:\/\/doi.org\/10.1128\/mcb.00024-18.","DOI":"10.1128\/mcb.00024-18"},{"issue":"1","key":"1013_CR33","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1038\/s41598-019-39229-8","volume":"19","author":"H Izumi","year":"2019","unstructured":"Izumi H, Li Y, Shibaki M, et al. Recycling endosomal CD133 functions as an inhibitor of autophagy at the pericentrosomal region. Sci Rep Feb. 2019;19(1):2236. https:\/\/doi.org\/10.1038\/s41598-019-39229-8.","journal-title":"Sci Rep Feb"},{"issue":"4","key":"1013_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/stmcls\/sxac007","volume":"29","author":"H Izumi","year":"2022","unstructured":"Izumi H, Li Y, Yasunami M, et al. Asymmetric Pericentrosomal CD133 Endosomes Induce the Unequal Autophagic Activity During Cytokinesis in CD133-Positive Human Neuroblastoma Cells. Stem Cells Apr. 2022;29(4):371\u201384. https:\/\/doi.org\/10.1093\/stmcls\/sxac007.","journal-title":"Stem Cells Apr"},{"issue":"2","key":"1013_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/0008-5472.Can-09-1820","volume":"15","author":"K Kemper","year":"2010","unstructured":"Kemper K, Sprick MR, de Bree M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res Jan. 2010;15(2):719\u201329. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-1820.","journal-title":"Cancer Res Jan"},{"issue":"9","key":"1013_CR36","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00109-008-0357-8","volume":"86","author":"S Bidlingmaier","year":"2008","unstructured":"Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) Sep. 2008;86(9):1025\u201332. https:\/\/doi.org\/10.1007\/s00109-008-0357-8.","journal-title":"J Mol Med (Berl) Sep"},{"issue":"2","key":"1013_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1034\/j.1600-0854.2001.020202.x","volume":"2","author":"D Corbeil","year":"2001","unstructured":"Corbeil D, R\u00f6per K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic Feb. 2001;2(2):82\u201391. https:\/\/doi.org\/10.1034\/j.1600-0854.2001.020202.x.","journal-title":"Traffic Feb"},{"issue":"24","key":"1013_CR38","doi-asserted-by":"publisher","first-page":"20650","DOI":"10.18632\/oncotarget.4115","volume":"21","author":"Y Liu","year":"2015","unstructured":"Liu Y, Ren S, Xie L, et al. Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth. Oncotarget Aug. 2015;21(24):20650\u201360. https:\/\/doi.org\/10.18632\/oncotarget.4115.","journal-title":"Oncotarget Aug"},{"issue":"6","key":"1013_CR39","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2003-06-1881","volume":"15","author":"SV Shmelkov","year":"2004","unstructured":"Shmelkov SV, Jun L, St Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood Mar. 2004;15(6):2055\u201361. https:\/\/doi.org\/10.1182\/blood-2003-06-1881.","journal-title":"Blood Mar"},{"key":"1013_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4614-5894-4_1","volume":"777","author":"D Corbeil","year":"2013","unstructured":"Corbeil D, Karbanov\u00e1 J, Fargeas CA, J\u00e1szai J. Prominin-1 (CD133): Molecular and Cellular Features Across Species. Adv Exp Med Biol. 2013;777:3\u201324. https:\/\/doi.org\/10.1007\/978-1-4614-5894-4_1.","journal-title":"Adv Exp Med Biol"},{"issue":"Pt 18","key":"1013_CR41","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1242\/jcs.01315","volume":"15","author":"CA Fargeas","year":"2004","unstructured":"Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB, Corbeil D. Identification of novel Prominin-1\/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci Aug. 2004;15(Pt 18):4301\u201311. https:\/\/doi.org\/10.1242\/jcs.01315.","journal-title":"J Cell Sci Aug"},{"issue":"10","key":"1013_CR42","doi-asserted-by":"publisher","first-page":"e0164079","DOI":"10.1371\/journal.pone.0164079","volume":"11","author":"K Thamm","year":"2016","unstructured":"Thamm K, Graupner S, Werner C, Huttner WB, Corbeil D. Monoclonal Antibodies 13A4 and AC133 Do Not Recognize the Canine Ortholog of Mouse and Human Stem Cell Antigen Prominin-1 (CD133). PLoS ONE. 2016;11(10):e0164079. https:\/\/doi.org\/10.1371\/journal.pone.0164079.","journal-title":"PLoS ONE"},{"issue":"3","key":"1013_CR43","doi-asserted-by":"publisher","first-page":"e17590","DOI":"10.1371\/journal.pone.0017590","volume":"2","author":"J J\u00e1szai","year":"2011","unstructured":"J\u00e1szai J, Fargeas CA, Graupner S, et al. Distinct and conserved prominin-1\/CD133-positive retinal cell populations identified across species. PLoS One Mar. 2011;2(3):e17590. https:\/\/doi.org\/10.1371\/journal.pone.0017590.","journal-title":"PLoS One Mar"},{"issue":"30","key":"1013_CR44","doi-asserted-by":"publisher","first-page":"15540","DOI":"10.1074\/jbc.M115.712976","volume":"22","author":"C Liu","year":"2016","unstructured":"Liu C, Li Y, Xing Y, et al. The Interaction between Cancer Stem Cell Marker CD133 and Src Protein Promotes Focal Adhesion Kinase (FAK) Phosphorylation and Cell Migration. J Biol Chem Jul. 2016;22(30):15540\u201350. https:\/\/doi.org\/10.1074\/jbc.M115.712976.","journal-title":"J Biol Chem Jul"},{"issue":"11","key":"1013_CR45","doi-asserted-by":"publisher","first-page":"e28053","DOI":"10.1371\/journal.pone.0028053","volume":"6","author":"YS Chen","year":"2011","unstructured":"Chen YS, Wu MJ, Huang CY, et al. CD133\/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS ONE. 2011;6(11):e28053. https:\/\/doi.org\/10.1371\/journal.pone.0028053.","journal-title":"PLoS ONE"},{"issue":"3","key":"1013_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/path.4086","volume":"229","author":"P Grosse-Gehling","year":"2013","unstructured":"Grosse-Gehling P, Fargeas CA, Dittfeld C, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol Feb. 2013;229(3):355\u201378. https:\/\/doi.org\/10.1002\/path.4086.","journal-title":"J Pathol Feb"},{"issue":"1","key":"1013_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12015-023-10647-6","volume":"20","author":"AP Moreno-Londo\u00f1o","year":"2024","unstructured":"Moreno-Londo\u00f1o AP, Robles-Flores M. Functional Roles of CD133: More than Stemness Associated Factor Regulated by the Microenvironment. Stem Cell Rev Rep Jan. 2024;20(1):25\u201351. https:\/\/doi.org\/10.1007\/s12015-023-10647-6.","journal-title":"Stem Cell Rev Rep Jan"},{"issue":"4","key":"1013_CR48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1369\/0022155411400867","volume":"59","author":"SK Hermansen","year":"2011","unstructured":"Hermansen SK, Christensen KG, Jensen SS, Kristensen BW. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem Apr. 2011;59(4):391\u2013407. https:\/\/doi.org\/10.1369\/0022155411400867.","journal-title":"J Histochem Cytochem Apr"},{"issue":"11","key":"1013_CR49","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.jmb.2014.02.012","volume":"29","author":"AB Mak","year":"2014","unstructured":"Mak AB, Pehar M, Nixon AM, et al. Post-translational regulation of CD133 by ATase1\/ATase2-mediated lysine acetylation. J Mol Biol May. 2014;29(11):2175\u201382. https:\/\/doi.org\/10.1016\/j.jmb.2014.02.012.","journal-title":"J Mol Biol May"},{"issue":"46","key":"1013_CR50","doi-asserted-by":"publisher","first-page":"32044","DOI":"10.1074\/jbc.M114.585547","volume":"14","author":"Y Ding","year":"2014","unstructured":"Ding Y, Dellisanti CD, Ko MH, Czajkowski C, Puglielli L. The endoplasmic reticulum-based acetyltransferases, ATase1 and ATase2, associate with the oligosaccharyltransferase to acetylate correctly folded polypeptides. J Biol Chem Nov. 2014;14(46):32044\u201355. https:\/\/doi.org\/10.1074\/jbc.M114.585547.","journal-title":"J Biol Chem Nov"},{"issue":"3","key":"1013_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/jb\/mvq062","volume":"148","author":"F Zhou","year":"2010","unstructured":"Zhou F, Cui C, Ge Y, et al. Alpha2,3-Sialylation regulates the stability of stem cell marker CD133. J Biochem Sep. 2010;148(3):273\u201380. https:\/\/doi.org\/10.1093\/jb\/mvq062.","journal-title":"J Biochem Sep"},{"issue":"17","key":"1013_CR52","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.1073\/pnas.1217002110","volume":"23","author":"Y Wei","year":"2013","unstructured":"Wei Y, Jiang Y, Zou F, et al. Activation of PI3K\/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A Apr. 2013;23(17):6829\u201334. https:\/\/doi.org\/10.1073\/pnas.1217002110.","journal-title":"Proc Natl Acad Sci U S A Apr"},{"issue":"26","key":"1013_CR53","doi-asserted-by":"publisher","first-page":"e2202216","DOI":"10.1002\/advs.202202216","volume":"9","author":"Y Wei","year":"2022","unstructured":"Wei Y, Chen Q, Huang S, et al. The Interaction between DNMT1 and High-Mannose CD133 Maintains the Slow-Cycling State and Tumorigenic Potential of Glioma Stem Cell. Adv Sci (Weinh) Sep. 2022;9(26):e2202216. https:\/\/doi.org\/10.1002\/advs.202202216.","journal-title":"Adv Sci (Weinh) Sep"},{"issue":"7","key":"1013_CR54","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/1873-3468.13358","volume":"593","author":"Y Li","year":"2019","unstructured":"Li Y, Shi D, Yang F, et al. Complex N-glycan promotes CD133 mono-ubiquitination and secretion. FEBS Lett Apr. 2019;593(7):719\u201331. https:\/\/doi.org\/10.1002\/1873-3468.13358.","journal-title":"FEBS Lett Apr"},{"issue":"15","key":"1013_CR55","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/onc.2014.141","volume":"9","author":"O Shimozato","year":"2015","unstructured":"Shimozato O, Waraya M, Nakashima K, et al. Receptor-type protein tyrosine phosphatase \u03ba directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene Apr. 2015;9(15):1949\u201360. https:\/\/doi.org\/10.1038\/onc.2014.141.","journal-title":"Oncogene Apr"},{"issue":"5","key":"1013_CR56","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/2211-5463.12636","volume":"9","author":"M Matsushita","year":"2019","unstructured":"Matsushita M, Mori Y, Uchiumi K, et al. PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133. FEBS Open Bio May. 2019;9(5):935\u201346. https:\/\/doi.org\/10.1002\/2211-5463.12636.","journal-title":"FEBS Open Bio May"},{"key":"1013_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.canlet.2018.09.009","volume":"438","author":"S Kim","year":"2018","unstructured":"Kim S, Cho CY, Lee D, et al. CD133-induced TM4SF5 expression promotes sphere growth via recruitment and blocking of protein tyrosine phosphatase receptor type F (PTPRF). Cancer Lett Dec 1. 2018;438:219\u201331. https:\/\/doi.org\/10.1016\/j.canlet.2018.09.009.","journal-title":"Cancer Lett Dec 1"},{"issue":"1","key":"1013_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/tra.12618","volume":"20","author":"K Thamm","year":"2019","unstructured":"Thamm K, \u0160imait\u0117 D, Karbanov\u00e1 J, et al. Prominin-1 (CD133) modulates the architecture and dynamics of microvilli. Traffic Jan. 2019;20(1):39\u201360. https:\/\/doi.org\/10.1111\/tra.12618.","journal-title":"Traffic Jan"},{"issue":"9","key":"1013_CR59","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.febslet.2010.01.050","volume":"3","author":"D Corbeil","year":"2010","unstructured":"Corbeil D, Marzesco AM, Wilsch-Br\u00e4uninger M, Huttner WB. The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro)epithelial cell differentiation. FEBS Lett May. 2010;3(9):1659\u201364. https:\/\/doi.org\/10.1016\/j.febslet.2010.01.050.","journal-title":"FEBS Lett May"},{"issue":"2","key":"1013_CR60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jbiomech.2011.10.039","volume":"10","author":"D Kabaso","year":"2012","unstructured":"Kabaso D, Bobrovska N, G\u00f3\u017ad\u017a W, et al. On the role of membrane anisotropy and BAR proteins in the stability of tubular membrane structures. J Biomech Jan. 2012;10(2):231\u20138. https:\/\/doi.org\/10.1016\/j.jbiomech.2011.10.039.","journal-title":"J Biomech Jan"},{"issue":"9","key":"1013_CR61","doi-asserted-by":"publisher","first-page":"e73941","DOI":"10.1371\/journal.pone.0073941","volume":"8","author":"N Bobrovska","year":"2013","unstructured":"Bobrovska N, G\u00f3\u017ad\u017a W, Kralj-Igli\u010d V, Igli\u010d A. On the role of anisotropy of membrane components in formation and stabilization of tubular structures in multicomponent membranes. PLoS ONE. 2013;8(9):e73941. https:\/\/doi.org\/10.1371\/journal.pone.0073941.","journal-title":"PLoS ONE"},{"issue":"9","key":"1013_CR62","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/35023524","volume":"2","author":"K R\u00f6per","year":"2000","unstructured":"R\u00f6per K, Corbeil D, Huttner WB. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat Cell Biol Sep. 2000;2(9):582\u201392. https:\/\/doi.org\/10.1038\/35023524.","journal-title":"Nat Cell Biol Sep"},{"issue":"12","key":"1013_CR63","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1210\/endo.139.12.6390","volume":"139","author":"H Li","year":"1998","unstructured":"Li H, Papadopoulos V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition\/interaction amino acid sequence and consensus pattern. Endocrinology Dec. 1998;139(12):4991\u20137. https:\/\/doi.org\/10.1210\/endo.139.12.6390.","journal-title":"Endocrinology Dec"},{"key":"1013_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fphys.2013.00031","volume":"4","author":"J Fantini","year":"2013","unstructured":"Fantini J, Barrantes FJ. How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains. Front Physiol. 2013;4:31. https:\/\/doi.org\/10.3389\/fphys.2013.00031.","journal-title":"Front Physiol"},{"issue":"Pt 13","key":"1013_CR65","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1242\/jcs.02439","volume":"1","author":"AM Marzesco","year":"2005","unstructured":"Marzesco AM, Janich P, Wilsch-Br\u00e4uninger M, et al. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci Jul. 2005;1(Pt 13):2849\u201358. https:\/\/doi.org\/10.1242\/jcs.02439.","journal-title":"J Cell Sci Jul"},{"issue":"4","key":"1013_CR66","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1083\/jcb.200608137","volume":"12","author":"V Dubreuil","year":"2007","unstructured":"Dubreuil V, Marzesco AM, Corbeil D, Huttner WB, Wilsch-Br\u00e4uninger M. Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1. J Cell Biol Feb. 2007;12(4):483\u201395. https:\/\/doi.org\/10.1083\/jcb.200608137.","journal-title":"J Cell Biol Feb"},{"issue":"5","key":"1013_CR67","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.febslet.2009.01.048","volume":"4","author":"AM Marzesco","year":"2009","unstructured":"Marzesco AM, Wilsch-Br\u00e4uninger M, Dubreuil V, et al. Release of extracellular membrane vesicles from microvilli of epithelial cells is enhanced by depleting membrane cholesterol. FEBS Lett Mar. 2009;4(5):897\u2013902. https:\/\/doi.org\/10.1016\/j.febslet.2009.01.048.","journal-title":"FEBS Lett Mar"},{"issue":"1","key":"1013_CR68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12951-025-03102-w","volume":"29","author":"J Karbanov\u00e1","year":"2025","unstructured":"Karbanov\u00e1 J, Thamm K, Fargeas CA, Deniz IA, Lorico A, Corbeil D. Prominosomes - a particular class of extracellular vesicles containing prominin-1\/CD133? J Nanobiotechnology Jan. 2025;29(1):61. https:\/\/doi.org\/10.1186\/s12951-025-03102-w.","journal-title":"J Nanobiotechnology Jan"},{"key":"1013_CR69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1476-4598-12-62","volume":"14","author":"G Rappa","year":"2013","unstructured":"Rappa G, Mercapide J, Anzanello F, Pope RM, Lorico A. Biochemical and biological characterization of exosomes containing prominin-1\/CD133. Mol Cancer Jun. 2013;14:12:62. https:\/\/doi.org\/10.1186\/1476-4598-12-62.","journal-title":"Mol Cancer Jun"},{"issue":"7","key":"1013_CR70","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.ajpath.2017.03.015","volume":"187","author":"D Lucchetti","year":"2017","unstructured":"Lucchetti D, Calap\u00e0 F, Palmieri V, et al. Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells. Am J Pathol Jul. 2017;187(7):1633\u201347. https:\/\/doi.org\/10.1016\/j.ajpath.2017.03.015.","journal-title":"Am J Pathol Jul"},{"issue":"3","key":"1013_CR71","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1096\/fj.201802018R","volume":"33","author":"M Kang","year":"2019","unstructured":"Kang M, Kim S, Ko J. Roles of CD133 in microvesicle formation and oncoprotein trafficking in colon cancer. Faseb j Mar. 2019;33(3):4248\u201360. https:\/\/doi.org\/10.1096\/fj.201802018R.","journal-title":"Faseb j Mar"},{"issue":"7","key":"1013_CR72","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/emmm.201100147","volume":"3","author":"N Bauer","year":"2011","unstructured":"Bauer N, Wilsch-Br\u00e4uninger M, Karbanov\u00e1 J, et al. Haematopoietic stem cell differentiation promotes the release of prominin-1\/CD133-containing membrane vesicles\u2013a role of the endocytic-exocytic pathway. EMBO Mol Med Jul. 2011;3(7):398\u2013409. https:\/\/doi.org\/10.1002\/emmm.201100147.","journal-title":"EMBO Mol Med Jul"},{"issue":"11","key":"1013_CR73","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.exphem.2016.07.006","volume":"44","author":"D Reichert","year":"2016","unstructured":"Reichert D, Scheinpflug J, Karbanov\u00e1 J, Freund D, Bornh\u00e4user M, Corbeil D. Tunneling nanotubes mediate the transfer of stem cell marker CD133 between hematopoietic progenitor cells. Exp Hematol Nov. 2016;44(11):1092\u2013e11122. https:\/\/doi.org\/10.1016\/j.exphem.2016.07.006.","journal-title":"Exp Hematol Nov"},{"key":"1013_CR74","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2019.12.009","volume":"28","author":"Z Wang","year":"2020","unstructured":"Wang Z, Liu W, Wang C, Li Y, Ai Z. Acetylcholine promotes the self-renewal and immune escape of CD133\u2009+\u2009thyroid cancer cells through activation of CD133-Akt pathway. Cancer Lett Feb. 2020;28:471:116\u201324. https:\/\/doi.org\/10.1016\/j.canlet.2019.12.009.","journal-title":"Cancer Lett Feb"},{"issue":"6","key":"1013_CR75","first-page":"967","volume":"19","author":"Y Katoh","year":"2007","unstructured":"Katoh Y, Katoh M. Comparative genomics on PROM1 gene encoding stem cell marker CD133. Int J Mol Med Jun. 2007;19(6):967\u201370.","journal-title":"Int J Mol Med Jun"},{"issue":"34","key":"1013_CR76","doi-asserted-by":"publisher","first-page":"12682","DOI":"10.1073\/pnas.0404875101","volume":"24","author":"KH Emami","year":"2004","unstructured":"Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A Aug. 2004;24(34):12682\u20137. https:\/\/doi.org\/10.1073\/pnas.0404875101.","journal-title":"Proc Natl Acad Sci U S A Aug"},{"issue":"1","key":"1013_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12964-018-0222-5","volume":"12","author":"Y Tang","year":"2018","unstructured":"Tang Y, Berlind J, Mavila N. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells. Cell Commun Signal Mar. 2018;12(1):9. https:\/\/doi.org\/10.1186\/s12964-018-0222-5.","journal-title":"Cell Commun Signal Mar"},{"issue":"9","key":"1013_CR78","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s41418-022-00969-2","volume":"29","author":"K Liu","year":"2022","unstructured":"Liu K, Jiang L, Shi Y, et al. Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation. Cell Death Differ Sep. 2022;29(9):1834\u201349. https:\/\/doi.org\/10.1038\/s41418-022-00969-2.","journal-title":"Cell Death Differ Sep"},{"issue":"2","key":"1013_CR79","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/15548627.2016.1260808","volume":"13","author":"T Sharif","year":"2017","unstructured":"Sharif T, Martell E, Dai C, et al. Autophagic homeostasis is required for the pluripotency of cancer stem cells. Autophagy Feb. 2017;13(2):264\u201384. https:\/\/doi.org\/10.1080\/15548627.2016.1260808.","journal-title":"Autophagy Feb"},{"issue":"5","key":"1013_CR80","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrc3261","volume":"19","author":"A Marusyk","year":"2012","unstructured":"Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer Apr. 2012;19(5):323\u201334. https:\/\/doi.org\/10.1038\/nrc3261.","journal-title":"Nat Rev Cancer Apr"},{"issue":"12","key":"1013_CR81","doi-asserted-by":"publisher","first-page":"21642","DOI":"10.1002\/jcp.28824","volume":"234","author":"M Aghajani","year":"2019","unstructured":"Aghajani M, Mansoori B, Mohammadi A, Asadzadeh Z, Baradaran B. New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation. J Cell Physiol Dec. 2019;234(12):21642\u201361. https:\/\/doi.org\/10.1002\/jcp.28824.","journal-title":"J Cell Physiol Dec"},{"issue":"9","key":"1013_CR82","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.18632\/oncotarget.7054","volume":"7","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Peng J, Zhang E, et al. CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis. Oncotarget Mar 1. 2016;7(9):10023\u201336. https:\/\/doi.org\/10.18632\/oncotarget.7054.","journal-title":"Oncotarget Mar 1"},{"issue":"2","key":"1013_CR83","doi-asserted-by":"publisher","first-page":"e56380","DOI":"10.1371\/journal.pone.0056380","volume":"8","author":"S Chen","year":"2013","unstructured":"Chen S, Song X, Chen Z, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS ONE. 2013;8(2):e56380. https:\/\/doi.org\/10.1371\/journal.pone.0056380.","journal-title":"PLoS ONE"},{"issue":"3","key":"1013_CR84","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"13","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell Sep. 2007;13(3):313\u201323. https:\/\/doi.org\/10.1016\/j.stem.2007.06.002.","journal-title":"Cell Stem Cell Sep"},{"issue":"3","key":"1013_CR85","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/modpathol.2011.170","volume":"25","author":"J Zhang","year":"2012","unstructured":"Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol Mar. 2012;25(3):456\u201364. https:\/\/doi.org\/10.1038\/modpathol.2011.170.","journal-title":"Mod Pathol Mar"},{"key":"1013_CR86","doi-asserted-by":"publisher","unstructured":"Pospieszna J, Dams-Kozlowska H, Udomsak W, Murias M, Kucinska M. Unmasking the deceptive nature of cancer stem cells: the role of CD133 in revealing their secrets. Int J Mol Sci. 2023;24(13). https:\/\/doi.org\/10.3390\/ijms241310910.","DOI":"10.3390\/ijms241310910"},{"key":"1013_CR87","doi-asserted-by":"publisher","unstructured":"Schmohl JU, Vallera DA. CD133, selectively targeting the root of cancer. Toxins (Basel). 2016;8(6). https:\/\/doi.org\/10.3390\/toxins8060165.","DOI":"10.3390\/toxins8060165"},{"issue":"5","key":"1013_CR88","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/0022034510393511","volume":"90","author":"M Damek-Poprawa","year":"2011","unstructured":"Damek-Poprawa M, Volgina A, Korostoff J, et al. Targeted inhibition of CD133\u2009+\u2009cells in oral cancer cell lines. J Dent Res May. 2011;90(5):638\u201345. https:\/\/doi.org\/10.1177\/0022034510393511.","journal-title":"J Dent Res May"},{"issue":"1\u20132","key":"1013_CR89","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jim.2010.07.007","volume":"30","author":"SK Swaminathan","year":"2010","unstructured":"Swaminathan SK, Olin MR, Forster CL, Cruz KS, Panyam J, Ohlfest JR. Identification of a novel monoclonal antibody recognizing CD133. J Immunol Methods Sep. 2010;30(1\u20132):110\u20135. https:\/\/doi.org\/10.1016\/j.jim.2010.07.007.","journal-title":"J Immunol Methods Sep"},{"issue":"10","key":"1013_CR90","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1158\/1535-7163.Mct-11-0206","volume":"10","author":"NN Waldron","year":"2011","unstructured":"Waldron NN, Kaufman DS, Oh S, et al. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther Oct. 2011;10(10):1829\u201338. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0206.","journal-title":"Mol Cancer Ther Oct"},{"issue":"3","key":"1013_CR91","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11523-013-0290-9","volume":"9","author":"NN Waldron","year":"2014","unstructured":"Waldron NN, Barsky SH, Dougherty PR, Vallera DA. A bispecific EpCAM\/CD133-targeted toxin is effective against carcinoma. Target Oncol Sep. 2014;9(3):239\u201349. https:\/\/doi.org\/10.1007\/s11523-013-0290-9.","journal-title":"Target Oncol Sep"},{"issue":"6","key":"1013_CR92","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/cji.0000000000000086","volume":"38","author":"L Zhao","year":"2015","unstructured":"Zhao L, Yang Y, Zhou P, et al. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody. J Immunother Jul-Aug. 2015;38(6):217\u201328. https:\/\/doi.org\/10.1097\/cji.0000000000000086.","journal-title":"J Immunother Jul-Aug"},{"issue":"3","key":"1013_CR93","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","volume":"11","author":"JU Schmohl","year":"2016","unstructured":"Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133\u2009+\u2009Colorectal Cancer Cells. Target Oncol Jun. 2016;11(3):353\u201361. https:\/\/doi.org\/10.1007\/s11523-015-0391-8.","journal-title":"Target Oncol Jun"},{"issue":"4","key":"1013_CR94","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.4143\/crt.2016.491","volume":"49","author":"JU Schmohl","year":"2017","unstructured":"Schmohl JU, Felices M, Oh F, et al. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Res Treat Oct. 2017;49(4):1140\u201352. https:\/\/doi.org\/10.4143\/crt.2016.491.","journal-title":"Cancer Res Treat Oct"},{"issue":"45","key":"1013_CR95","doi-asserted-by":"publisher","first-page":"73830","DOI":"10.18632\/oncotarget.12073","volume":"7","author":"JU Schmohl","year":"2016","unstructured":"Schmohl JU, Felices M, Todhunter D, Taras E, Miller JS, Vallera DA. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker. Oncotarget Nov 8. 2016;7(45):73830\u201344. https:\/\/doi.org\/10.18632\/oncotarget.12073.","journal-title":"Oncotarget Nov 8"},{"issue":"3","key":"1013_CR96","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jconrel.2013.07.014","volume":"10","author":"SK Swaminathan","year":"2013","unstructured":"Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release Nov. 2013;10(3):280\u20137. https:\/\/doi.org\/10.1016\/j.jconrel.2013.07.014.","journal-title":"J Control Release Nov"},{"issue":"4","key":"1013_CR97","doi-asserted-by":"publisher","first-page":"34","DOI":"10.32607\/20758251-2013-5-4-34-43","volume":"5","author":"AV Lakhin","year":"2013","unstructured":"Lakhin AV, Tarantul VZ, Gening LV. Aptamers: problems, solutions and prospects. Acta Naturae Oct. 2013;5(4):34\u201343.","journal-title":"Acta Naturae Oct"},{"issue":"27","key":"1013_CR98","doi-asserted-by":"publisher","first-page":"44004","DOI":"10.18632\/oncotarget.16868","volume":"4","author":"D Weng","year":"2017","unstructured":"Weng D, Jin X, Qin S, et al. Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice. Oncotarget Jul. 2017;4(27):44004\u201314. https:\/\/doi.org\/10.18632\/oncotarget.16868.","journal-title":"Oncotarget Jul"},{"issue":"6","key":"1013_CR99","doi-asserted-by":"publisher","first-page":"862","DOI":"10.7150\/thno.12890","volume":"6","author":"H Jing","year":"2016","unstructured":"Jing H, Weidensteiner C, Reichardt W, et al. Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics. 2016;6(6):862\u201374. https:\/\/doi.org\/10.7150\/thno.12890.","journal-title":"Theranostics"},{"key":"1013_CR100","doi-asserted-by":"publisher","unstructured":"Olsen CE, Cheung LH, Weyergang A, et al. Design, characterization, and evaluation of scFvCD133\/rGelonin: A CD133-targeting recombinant immunotoxin for use in combination with photochemical internalization. J Clin Med. 2019;9(1). https:\/\/doi.org\/10.3390\/jcm9010068.","DOI":"10.3390\/jcm9010068"},{"issue":"5","key":"1013_CR101","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/mab.2017.0031","volume":"36","author":"S Itai","year":"2017","unstructured":"Itai S, Fujii Y, Nakamura T, et al. Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry. Monoclon Antib Immunodiagn Immunother Oct. 2017;36(5):231\u20135. https:\/\/doi.org\/10.1089\/mab.2017.0031.","journal-title":"Monoclon Antib Immunodiagn Immunother Oct"},{"issue":"2","key":"1013_CR102","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/mab.2019.0002","volume":"38","author":"Y Kato","year":"2019","unstructured":"Kato Y, Ohishi T, Yamada S, et al. Anti-CD133 Monoclonal Antibody CMab-43 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer. Monoclon Antib Immunodiagn Immunother Apr. 2019;38(2):75\u20138. https:\/\/doi.org\/10.1089\/mab.2019.0002.","journal-title":"Monoclon Antib Immunodiagn Immunother Apr"},{"issue":"4","key":"1013_CR103","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/hum.2017.234","volume":"30","author":"B Hu","year":"2019","unstructured":"Hu B, Zou Y, Zhang L, et al. Nucleofection with Plasmid DNA for CRISPR\/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells. Hum Gene Ther Apr. 2019;30(4):446\u201358. https:\/\/doi.org\/10.1089\/hum.2017.234.","journal-title":"Hum Gene Ther Apr"},{"issue":"1","key":"1013_CR104","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","volume":"5","author":"KC Feng","year":"2017","unstructured":"Feng KC, Guo YL, Liu Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol Jan. 2017;5(1):4. https:\/\/doi.org\/10.1186\/s13045-016-0378-7.","journal-title":"J Hematol Oncol Jan"},{"issue":"10","key":"1013_CR105","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s00262-021-02891-x","volume":"70","author":"Y Han","year":"2021","unstructured":"Han Y, Sun B, Cai H, Xuan Y. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy. Cancer Immunol Immunother Oct. 2021;70(10):2795\u2013803. https:\/\/doi.org\/10.1007\/s00262-021-02891-x.","journal-title":"Cancer Immunol Immunother Oct"},{"issue":"2","key":"1013_CR106","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/leu.2016.194","volume":"31","author":"SP Koerner","year":"2017","unstructured":"Koerner SP, Andr\u00e9 MC, Leibold JS, et al. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. Leukemia Feb. 2017;31(2):459\u201369. https:\/\/doi.org\/10.1038\/leu.2016.194.","journal-title":"Leukemia Feb"},{"issue":"1","key":"1013_CR107","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/sj.bjc.6604437","volume":"8","author":"LM Smith","year":"2008","unstructured":"Smith LM, Nesterova A, Ryan MC, et al. CD133\/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer Jul. 2008;8(1):100\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6604437.","journal-title":"Br J Cancer Jul"},{"key":"1013_CR108","doi-asserted-by":"publisher","unstructured":"Jin C, Yang Z, Yang J et al. Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells. J Nanopart Res. 2013;16(1):2157. https:\/\/doi.org\/10.1007\/s11051-013-2157-5.","DOI":"10.1007\/s11051-013-2157-5"},{"issue":"sup1","key":"1013_CR109","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/21691401.2018.1446969","volume":"46","author":"M Alibolandi","year":"2018","unstructured":"Alibolandi M, Abnous K, Anvari S, Mohammadi M, Ramezani M, Taghdisi SM. CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1159\u201369. https:\/\/doi.org\/10.1080\/21691401.2018.1446969.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"1","key":"1013_CR110","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2012.11.032","volume":"1","author":"S Shigdar","year":"2013","unstructured":"Shigdar S, Qiao L, Zhou SF, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett Mar. 2013;1(1):84\u201395. https:\/\/doi.org\/10.1016\/j.canlet.2012.11.032.","journal-title":"Cancer Lett Mar"},{"key":"1013_CR111","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.actbio.2016.10.009","volume":"47","author":"JH Cho","year":"2017","unstructured":"Cho JH, Kim AR, Kim SH, Lee SJ, Chung H, Yoon MY. Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. Acta Biomater Jan 1. 2017;47:182\u201392. https:\/\/doi.org\/10.1016\/j.actbio.2016.10.009.","journal-title":"Acta Biomater Jan 1"},{"issue":"11","key":"1013_CR112","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jsps.2020.09.003","volume":"28","author":"K Dadashi Noshahr","year":"2020","unstructured":"Dadashi Noshahr K, Shamsi F, Valtchev P, et al. Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro. Saudi Pharm J Nov. 2020;28(11):1392\u2013401. https:\/\/doi.org\/10.1016\/j.jsps.2020.09.003.","journal-title":"Saudi Pharm J Nov"},{"key":"1013_CR113","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fchem.2020.00649","volume":"8","author":"Z Wang","year":"2020","unstructured":"Wang Z, Sun M, Li W, Fan L, Zhou Y, Hu Z. A Novel CD133- and EpCAM-Targeted Liposome With Redox-Responsive Properties Capable of Synergistically Eliminating Liver Cancer Stem Cells. Front Chem. 2020;8:649. https:\/\/doi.org\/10.3389\/fchem.2020.00649.","journal-title":"Front Chem"},{"key":"1013_CR114","doi-asserted-by":"publisher","unstructured":"Rudnick JD, Fink KL, Landolfi JC, et al. Immunological targeting of CD133 in recurrent glioblastoma: a multicenter phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy. Meeting Abstract. J Clin Oncol. 2017;35. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.2059.","DOI":"10.1200\/JCO.2017.35.15_suppl.2059"},{"key":"1013_CR115","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.omto.2020.06.019","volume":"25","author":"ASS Do","year":"2020","unstructured":"Do ASS, Amano T, Edwards LA, Zhang L, De Peralta-Venturina M, Yu JS. CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model. Mol Ther Oncolytics Sep. 2020;25:18:295\u2013303. https:\/\/doi.org\/10.1016\/j.omto.2020.06.019.","journal-title":"Mol Ther Oncolytics Sep"},{"key":"1013_CR116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.omto.2021.05.006","volume":"24","author":"ASS Tay","year":"2021","unstructured":"Tay ASS, Amano T, Edwards LA, Yu JS. CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells. Mol Ther Oncolytics Sep. 2021;24:22:64\u201371. https:\/\/doi.org\/10.1016\/j.omto.2021.05.006.","journal-title":"Mol Ther Oncolytics Sep"},{"issue":"6","key":"1013_CR117","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1039\/d0bm01874k","volume":"21","author":"S Yan","year":"2021","unstructured":"Yan S, Tang D, Hong Z, et al. CD133 peptide-conjugated pyropheophorbide-a as a novel photosensitizer for targeted photodynamic therapy in colorectal cancer stem cells. Biomater Sci Mar. 2021;21(6):2020\u201331. https:\/\/doi.org\/10.1039\/d0bm01874k.","journal-title":"Biomater Sci Mar"},{"issue":"12","key":"1013_CR118","doi-asserted-by":"publisher","first-page":"e116114","DOI":"10.1371\/journal.pone.0116114","volume":"9","author":"NS Bayin","year":"2014","unstructured":"Bayin NS, Modrek AS, Dietrich A, et al. Selective lentiviral gene delivery to CD133-expressing human glioblastoma stem cells. PLoS ONE. 2014;9(12):e116114. https:\/\/doi.org\/10.1371\/journal.pone.0116114.","journal-title":"PLoS ONE"},{"key":"1013_CR119","doi-asserted-by":"publisher","first-page":"111364","DOI":"10.1016\/j.biopha.2021.111364","volume":"137","author":"Z Asadzadeh","year":"2021","unstructured":"Asadzadeh Z, Mansoori B, Mohammadi A, et al. The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomed Pharmacother May. 2021;137:111364. https:\/\/doi.org\/10.1016\/j.biopha.2021.111364.","journal-title":"Biomed Pharmacother May"},{"issue":"1","key":"1013_CR120","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2162-3619-2-17","volume":"1","author":"Z Li","year":"2013","unstructured":"Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol Jul. 2013;1(1):17. https:\/\/doi.org\/10.1186\/2162-3619-2-17.","journal-title":"Exp Hematol Oncol Jul"},{"issue":"6","key":"1013_CR121","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3727\/096368910x508997","volume":"19","author":"N Navarro-Alvarez","year":"2010","unstructured":"Navarro-Alvarez N, Kondo E, Kawamoto H, et al. Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transpl. 2010;19(6):865\u201377. https:\/\/doi.org\/10.3727\/096368910x508997.","journal-title":"Cell Transpl"},{"key":"1013_CR122","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.canlet.2021.05.003","volume":"10","author":"Z Liang","year":"2021","unstructured":"Liang Z, Wu B, Ji Z, et al. The binding of LDN193189 to CD133 C-terminus suppresses the tumorigenesis and immune escape of liver tumor-initiating cells. Cancer Lett Aug. 2021;10:513:90\u2013100. https:\/\/doi.org\/10.1016\/j.canlet.2021.05.003.","journal-title":"Cancer Lett Aug"},{"issue":"6","key":"1013_CR123","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jhep.2019.08.034","volume":"71","author":"Y Wei","year":"2019","unstructured":"Wei Y, Shi D, Liang Z, et al. IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells. J Hepatol Dec. 2019;71(6):1206\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.034.","journal-title":"J Hepatol Dec"},{"issue":"3","key":"1013_CR124","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3892\/ijo.2013.1787","volume":"42","author":"KS Lehnus","year":"2013","unstructured":"Lehnus KS, Donovan LK, Huang X, et al. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. Int J Oncol Mar. 2013;42(3):1011\u20137. https:\/\/doi.org\/10.3892\/ijo.2013.1787.","journal-title":"Int J Oncol Mar"},{"key":"1013_CR125","doi-asserted-by":"publisher","first-page":"153303382311636","DOI":"10.1177\/15330338231163677","volume":"22","author":"AG Quiroz Reyes","year":"2023","unstructured":"Quiroz Reyes AG, Lozano Sepulveda SA, Martinez-Acu\u00f1a N, et al. Cancer Stem Cell and Hepatic Stellate Cells in Hepatocellular Carcinoma. Technol Cancer Res Treat Jan-Dec. 2023;22:15330338231163677. https:\/\/doi.org\/10.1177\/15330338231163677.","journal-title":"Technol Cancer Res Treat Jan-Dec"},{"issue":"3\u20134","key":"1013_CR126","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1101\/gad.319889.118","volume":"1","author":"H Zhang","year":"2019","unstructured":"Zhang H, Brown RL, Wei Y, et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev Feb. 2019;1(3\u20134):166\u201379. https:\/\/doi.org\/10.1101\/gad.319889.118.","journal-title":"Genes Dev Feb"},{"issue":"2","key":"1013_CR127","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cam4.1968","volume":"8","author":"R Asai","year":"2019","unstructured":"Asai R, Tsuchiya H, Amisaki M, et al. CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line. Cancer Med Feb. 2019;8(2):773\u201382. https:\/\/doi.org\/10.1002\/cam4.1968.","journal-title":"Cancer Med Feb"},{"issue":"10","key":"1013_CR128","doi-asserted-by":"publisher","first-page":"11018","DOI":"10.18632\/oncotarget.6920","volume":"7","author":"H Tomita","year":"2016","unstructured":"Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget Mar 8. 2016;7(10):11018\u201332. https:\/\/doi.org\/10.18632\/oncotarget.6920.","journal-title":"Oncotarget Mar 8"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01013-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:02:52Z","timestamp":1791572572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-01013-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01013-y","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"25 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"137"}}